Tg Therapeutics (TGTX) Restructuring Costs (2011 - 2020)

Tg Therapeutics' Restructuring Costs history runs 10 years deep, the most recent figure standing at $16.2 million for Q4 2020.

• On a quarterly basis, Restructuring Costs rose 452.33% year-over-year to $16.2 million in Q4 2020; TTM through Dec 2020 was $41.5 million, a 336.85% increase from a year earlier, with the FY2020 full-year figure at $41.5 million, up 336.9% from the prior year.
• Restructuring Costs climbed to $16.2 million in Q4 2020 per TGTX's latest filing, from $11.6 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $16.2 million in Q4 2020 and bottomed at $1.1 million in Q1 2016.
• The 5-year median for Restructuring Costs is $1.9 million (2018), against an average of $3.5 million.
• Across the five-year window, Restructuring Costs dropped 8.02% in 2019 and surged 452.33% in 2020, its largest moves.
• Year by year, Restructuring Costs stood at $1.3 million in 2016, then surged by 33.55% to $1.8 million in 2017, then fell by 6.0% to $1.7 million in 2018, then surged by 76.04% to $2.9 million in 2019, then jumped by 452.33% to $16.2 million in 2020.
• Per Business Quant, the three latest TGTX Restructuring Costs figures stand at $16.2 million (Q4 2020), $11.6 million (Q3 2020), and $8.6 million (Q2 2020).